Noriko Tomita, Sho Saito, Junko Terada-Hirashima, Ayako Mikami, Yukari Uemura, Satoshi Kutsuna, Hidetoshi Nomoto, Kyoko Fujisawa, Maki Nagashima, Mari Terada, Shinobu Ashida, Shinichiro Morioka, Masahiro Satake, Akira Hangaishi, Tomiteru Togano, Katsuyuki Shiratori, Yuki Takamatsu, Kenji Maeda, Norio Ohmagari, Wataru Sugiura, Hiroaki Mitsuya
BACKGROUND: Coronavirus disease 2019 is a global public health concern. As of December 2020, the therapeutic agents approved for coronavirus disease 2019 in Japan were limited to two drugs: remdesivir, an antiviral drug, granted a Special Approval for Emergency on 7 May 2020, and dexamethasone, which has an anti-inflammatory effect. The aim of this study is to evaluate the efficacy of convalescent plasma collected from donors who recovered from coronavirus disease 2019. METHODS: This is an open-label, randomized controlled trial comprising two groups: a convalescent plasma and a standard-of-care group...
June 8, 2022: Life